Glenmark Specialty SA Receives U.S. FDA Approval For Fluticasone Propionate Inhalation Aerosol Usp, 44 Mcg Per Actuation, With 180-Day Competitive Generic Therapy Exclusivity
Glenmark Specialty SA Receives U.S. FDA Approval For Fluticasone Propionate Inhalation Aerosol Usp, 44 Mcg Per Actuation, With 180-Day Competitive Generic Therapy Exclusivity
Glenmark Specialty SA Receives U.S. FDA Approval For Fluticasone Propionate Inhalation Aerosol Usp, 44 Mcg Per Actuation, With 180-Day Competitive Generic Therapy Exclusivity
Sector
HEALTHCARE
News Type
MARKET
Impact Level
LOW
AI Sentiment
NEUTRAL
Published
09 May 2026
📎 Sources
Reuters | https://www.tradingview.com/news/reuters.com,2026:newsml_TUA3WW9DD:0-glenmark-specialty-sa-receives-u-s-fda-approval-for-fluticasone-propionate-inhalation-aerosol-usp-44-mcg-per-actuation-with-180-day-competitive-generic-therapy-exclusivity/